<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04920383</url>
  </required_header>
  <id_info>
    <org_study_id>AIS-B02</org_study_id>
    <nct_id>NCT04920383</nct_id>
  </id_info>
  <brief_title>ALPN-202 With PD-1 Inhibition in Advanced Malignancies</brief_title>
  <acronym>NEON-2</acronym>
  <official_title>An Open-label Study of ALPN-202 Combined With PD-1 Inhibition in Subjects With Advanced Malignancies (NEON-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alpine Immune Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alpine Immune Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a cohort-based, open-label dose escalation and expansion study in adults with&#xD;
      advanced solid tumors or lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 30 days after last dose of study drug</time_frame>
    <description>Type, incidence, and severity of adverse events as assessed by CTCAE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response</measure>
    <time_frame>Up to 30 days after last dose of study drug</time_frame>
    <description>Best observed objective responses as assessed by RECIST for solid tumors, or Lugano for lymphoma</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">323</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Dose Escalation and Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALPN-202 + Pembrolizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALPN-202</intervention_name>
    <description>Various doses</description>
    <arm_group_label>Dose Escalation and Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Varies</description>
    <arm_group_label>Dose Escalation and Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult 18 to 80 years old at screening&#xD;
&#xD;
          -  Pathologically confirmed, locally advanced or metastatic unresectable solid tumor, or&#xD;
             Hodgkin or Non-Hodgkin lymphoma (including transformed lymphoma) of an acceptable&#xD;
             histology:&#xD;
&#xD;
               1. that is eligible for treatment with a PD-1 or PD-L1 inhibitor, or&#xD;
&#xD;
               2. that is refractory or resistant to standard therapy, or&#xD;
&#xD;
               3. for which standard or curative therapy is not available.&#xD;
&#xD;
          -  Have received ≥ 2 prior systemic anti-cancer therapies (lymphoma subjects only)&#xD;
&#xD;
          -  Protocol-defined measurable disease&#xD;
&#xD;
          -  Available tumor biopsy representative of current disease&#xD;
&#xD;
          -  ECOG performance status grade 0-1&#xD;
&#xD;
          -  Life expectancy of ≥ 3 months&#xD;
&#xD;
          -  Recovery to Grade ≤ 1 for any non-laboratory toxicity resulting from previous&#xD;
             anticancer therapy prior to first dose of ALPN-202 (except alopecia, hearing loss,&#xD;
             Grade ≤ 2 neuropathy, or endocrinopathy managed with replacement therapy)&#xD;
&#xD;
          -  Adequate baseline hematologic, renal, and hepatic function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any history of ≥ Grade 3 immune-related adverse event (irAE)&#xD;
&#xD;
          -  Active or prior pneumonitis or interstitial lung disease&#xD;
&#xD;
          -  Presence of any active central nervous system metastases&#xD;
&#xD;
          -  Prior organ allograft or allogeneic hematopoietic stem cell transplantation&#xD;
&#xD;
          -  Any serious or uncontrolled health condition, which, in the opinion of the&#xD;
             Investigator, would place the subject at undue risk from the study, impair the ability&#xD;
             of the subject to receive protocol specified therapy, or interfere with the&#xD;
             interpretation of study results.&#xD;
&#xD;
          -  Receipt of any protocol-restricted therapy within the timeframes indicated:&#xD;
&#xD;
               1. PD-L1 inhibitors: 5 half-lives (e.g., atezolizumab, 135 days; avelumab, 31 days;&#xD;
                  durvalumab, 85 days)&#xD;
&#xD;
               2. PD-1 inhibitors: one scheduled standard dosing interval&#xD;
&#xD;
               3. Other checkpoint inhibitors, including CTLA-4 inhibitors (e.g., ipilimumab,&#xD;
                  tremelimumab): 4 weeks&#xD;
&#xD;
               4. Chemotherapy, small molecule anticancer agents (e.g., kinase inhibitors), or&#xD;
                  radiation: 2 weeks&#xD;
&#xD;
               5. Other monoclonal antibodies, antibody-drug conjugates, bispecific antibodies,&#xD;
                  antibody-like drugs, cytokines, cell therapies, or radioimmunoconjugates: 4 weeks&#xD;
&#xD;
          -  Any active, known, or suspected autoimmune disease&#xD;
&#xD;
          -  Systemic treatment with corticosteroids (&gt; 10 mg/day prednisone) or other&#xD;
             immunosuppressive medication&#xD;
&#xD;
          -  Any second malignancy active within the previous 3 years&#xD;
&#xD;
          -  Active infection requiring therapy at the time of the first dose of ALPN-202.&#xD;
&#xD;
          -  Known seropositivity for or active infection by human immunodeficiency virus,&#xD;
             hepatitis B or C, or or Severe Acute Respiratory Syndrome Coronavirus 2.&#xD;
&#xD;
          -  Known allergies, hypersensitivity, or intolerance to ALPN-202 or excipients in the&#xD;
             drug product formulation.&#xD;
&#xD;
          -  History of Grade 4 infusion-related, anaphylactic or allergic reaction to any previous&#xD;
             Fc-based protein therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanford Peng, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alpine Immune Sciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sean Lee</last_name>
    <phone>+1 905 690 5484</phone>
    <email>Sean.Lee@iconplc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site (212)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (301)</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (203)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site (215)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

